A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
Status:
Recruiting
Trial end date:
2025-12-22
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, placebo- and active-controlled, parallel-group, 24-week
trial to investigate the efficacy, safety, and tolerability of XXB750 in participants with
HFrEF/HFmrEF.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Sacubitril and valsartan sodium hydrate drug combination Valsartan